BACKGROUND: Thiopurines are used for many cancers, including acute lymphoblastic leukemia (ALL). Patients with an inherited host defect in thiopurine methyltransferase (TPMT) are at high risk for life-threatening toxicity if treated with conventional dosages, but the impact on antileukemic efficacy is less clear. MATERIALS AND METHODS: We treated thiopurine-sensitive BCR-ABL+Arf-null Tpmt+/+ ALL in Tpmt+/+, +/-, or -/- recipient mice to test the impact of the host polymorphism on antileukemic efficacy. RESULTS: Median survival was similar in untreated mice of different Tpmt genotypes (16-18 days). However, in mice treated with low-dose mercaptopurine (such as tolerated by TPMT-/- patients), the difference in 30-day leukemia-free survival by Tpmt genotype was profound: 5% (±9%) for Tpmt+/+ mice, 47% (±26%) for Tpmt+/- mice, and 85% (±14%) for Tpmt-/- mice (P=5×10), indicating a substantial impact of host Tpmt status on thiopurine effectiveness. Among Tpmt+/+ recipient mice, leukemia-free survival improved with higher doses of mercaptopurine (similar to doses tolerated by wild-type patients) compared with lower doses, and at higher doses was comparable (P=0.6) to the survival of Tpmt-/- mice treated with the lower dose. CONCLUSIONS: These findings support the notion that germline polymorphisms in Tpmt affect not only host tissue toxicity but also antitumor effectiveness.
BACKGROUND:Thiopurines are used for many cancers, including acute lymphoblastic leukemia (ALL). Patients with an inherited host defect in thiopurine methyltransferase (TPMT) are at high risk for life-threatening toxicity if treated with conventional dosages, but the impact on antileukemic efficacy is less clear. MATERIALS AND METHODS: We treated thiopurine-sensitive BCR-ABL+Arf-null Tpmt+/+ ALL in Tpmt+/+, +/-, or -/- recipient mice to test the impact of the host polymorphism on antileukemic efficacy. RESULTS: Median survival was similar in untreated mice of different Tpmt genotypes (16-18 days). However, in mice treated with low-dose mercaptopurine (such as tolerated by TPMT-/- patients), the difference in 30-day leukemia-free survival by Tpmt genotype was profound: 5% (±9%) for Tpmt+/+ mice, 47% (±26%) for Tpmt+/- mice, and 85% (±14%) for Tpmt-/- mice (P=5×10), indicating a substantial impact of host Tpmt status on thiopurine effectiveness. Among Tpmt+/+ recipient mice, leukemia-free survival improved with higher doses of mercaptopurine (similar to doses tolerated by wild-type patients) compared with lower doses, and at higher doses was comparable (P=0.6) to the survival of Tpmt-/- mice treated with the lower dose. CONCLUSIONS: These findings support the notion that germline polymorphisms in Tpmt affect not only host tissue toxicity but also antitumor effectiveness.
Authors: W E Evans; Y Y Hon; L Bomgaars; S Coutre; M Holdsworth; R Janco; D Kalwinsky; F Keller; Z Khatib; J Margolin; J Murray; J Quinn; Y Ravindranath; K Ritchey; W Roberts; Z R Rogers; D Schiff; C Steuber; F Tucci; N Kornegay; E Y Krynetski; M V Relling Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: M V Relling; M L Hancock; G K Rivera; J T Sandlund; R C Ribeiro; E Y Krynetski; C H Pui; W E Evans Journal: J Natl Cancer Inst Date: 1999-12-01 Impact factor: 13.506
Authors: Matthias Schwab; Elke Schäffeler; Claudia Marx; Christine Fischer; Thomas Lang; Christoph Behrens; Michael Gregor; Michel Eichelbaum; Ulrich M Zanger; Bernd A Kaskas Journal: Pharmacogenetics Date: 2002-08
Authors: Jun J Yang; Cheng Cheng; Meenakshi Devidas; Xueyuan Cao; Dario Campana; Wenjian Yang; Yiping Fan; Geoff Neale; Nancy Cox; Paul Scheet; Michael J Borowitz; Naomi J Winick; Paul L Martin; W Paul Bowman; Bruce Camitta; Gregory H Reaman; William L Carroll; Cheryl L Willman; Stephen P Hunger; William E Evans; Ching-Hon Pui; Mignon Loh; Mary V Relling Journal: Blood Date: 2012-09-24 Impact factor: 22.113
Authors: B A Bell; G N Brockway; J J Shuster; G Erdmann; S Sterikoff; B Bostrom; B M Camitta Journal: Pediatr Blood Cancer Date: 2004-08 Impact factor: 3.167
Authors: Emily R Finch; Laura J Janke; Lie Li; Monique A Payton; David A Jenkins; Kristine R Crews; Mary V Relling; Seth E Karol Journal: Pediatr Blood Cancer Date: 2021-12-05 Impact factor: 3.167
Authors: S E Karol; E Larsen; C Cheng; X Cao; W Yang; L B Ramsey; C A Fernandez; J R McCorkle; S W Paugh; R J Autry; E Lopez-Lopez; B Diouf; S Jeha; C-H Pui; E A Raetz; N J Winick; W L Carroll; S P Hunger; M L Loh; M Devidas; W E Evans; J J Yang; M V Relling Journal: Leukemia Date: 2017-01-18 Impact factor: 11.528
Authors: Laura B Ramsey; Laura J Janke; Monique A Payton; Xiangjun Cai; Steven W Paugh; Seth E Karol; Landry Kamdem Kamdem; Cheng Cheng; Richard T Williams; Sima Jeha; Ching-Hon Pui; William E Evans; Mary V Relling Journal: PLoS One Date: 2015-08-07 Impact factor: 3.240